Acola Corp., Formerly MegaChain.com, Ltd., Announces New Scientific Advisor, Robert A. Newman, Ph.D, Chief of Pharmacology, M.D. Anderson Cancer Center.

Business Editors/Health & Medical Writers

HOUSTON--(BUSINESS WIRE)--Nov. 14, 2001

Acola Corp., a Delaware corporation (formerly MegaChain.com, Ltd.)(OTCBB:ACAC) ("Acola") announced today that Dr. Newman has agreed to join the Acola team as a Scientific Advisor. Dr. Newman is Chief, Section of Clinical Pharmacology, Department of Clinical Investigation, at the University of Texas, M. D. Anderson Cancer Center in Houston, Texas, rated the No. 1 cancer facility in the United States in the most recent U.S. News & World Report survey of leading U.S. hospitals. Dr. Newman has researched ANVIRZEL(TM) over the past three years and written or co-authored six manuscripts regarding ANVIRZEL(TM), published in peer-reviewed medical journals. For more information, visit our Web site at www.acolacorp.com.

According to Acola's President and CEO, Robert B. Dillon, "Acola Corp. is gratified to have a scientist of Dr. Newman's distinction and reputation join the Acola team, and we all look forward to working with Dr. Newman over the next several years." Dr. Newman will assist Acola with all aspects of research and development and work with management in structuring Acola's testing and development plans for ANVIRZEL(TM) and other drugs in Latin America.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by Acola or on its behalf. These forward-looking statements are not historical facts, but reflect Acola's current expectations, estimates and projections. All statements contained in the press release which address future operating performance, events or developments that are expected to occur in the future (including statements relating to earnings expectations, sales of assets, or statements expressing general optimism about future operating results) are forward-looking statements. Although Acola believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved. Important factors that could cause actual results to differ materially from those in the forward-looking statements herein include success in marketing Anvirzel(TM) in Mexico, FDA approval of Anvirzel(TM) in the United States, development of Acola's market in Mexico, and conditions of the capital markets and equity markets during the periods covered by the forward-looking statements.